Taurus Vascular is a medical device company focused on improving long-term outcomes for patients with aortic aneurysms.

Taurus Vascular

Taurus Vascular | 371 followers on LinkedIn. Taurus Vascular is a medical device startup focused on transforming the standard of care for aortic aneurysm treatment | Taurus Vascular is a Houston-based medical device company focused on improving long-term outcomes for patients with aortic aneurysms. We are developing a minimally invasive catheter solution for addressing the most pressing complication of endovascular aortic aneurysm repair - endoleaks. If left untreated, endoleaks are potentially life-threatening and can lead to rupture of the aorta.

Founder & CEO at Taurus Vascular | Innovating Aortic Aneurysm Treatment | Medical Device Entrepreneur

Matthew Kuhn

Connect with our team at the 2025 LSI Emerging Medtech Summit!

I’m excited to be speaking at The MedTech Conference , October 15-17 in Toronto! I'll be sharing more about Taurus Vascular via MedTech Innovator 's Cardiovascular Surgery Showcase. Join me and my co-panelists Sanjay Shrivastava, Ph.D. of Innova Vascular, Inc. , Cormac Farrelly of LaNua Medical, and Timothy Murphy of Summa Therapeutics as we explore critical issues that impact the healthcare industry. I hope to see you there! https://lnkd.in/g_UCMhC4 #MedTechCon #MTC24 #Medtech #MedicalDevices #Startup

Taurus Vascular is developing a novel medical device technology to eliminate the negative effects of endoleaks after endovascular aortic aneurysm repair (EVAR), improving procedure outcomes and allowing patients to live longer, healthier lives. Watch their pitch video & like it on YouTube to vote for them to win the $10K #MTIBestVideo Matthew Kuhn https://lnkd.in/gJtfFeEV

MedTech Innovator

Taurus Vascular needs your support! We’re excited to participate in the 2024 MedTech Innovator Best Video Competition, and we need your help to win the $10,000 prize. Our mission is to transform the standard of care for aortic aneurysm treatment with our novel aortocaval shunt technology. Your engagement is crucial in helping us raise awareness about aortic aneurysms, showcase our innovation, and accelerate Taurus Vascular towards commercialization. How you can help: ▶ Watch our video on YouTube before the September 24th deadline: https://lnkd.in/gUNT7WbC 👍 Like the video on YouTube ➡ Share the video with your network to spread the word Every view and like brings us closer to the top. Thank you for supporting our team! #MedTechInnovator #Medtech #MedicalDevices #Startup #EVAR

Matthew Kuhn is the Founder & CEO of Taurus Vascular, a Houston-based medical device company dedicated to improving long-term outcomes for patients with aortic aneurysms. Under Matthew’s leadership, Taurus Vascular is developing an innovative medical device to reduce the risk and impact of endoleaks after endovascular aortic aneurysm repair (EVAR). Matthew holds a B.S. in Biomedical Engineering from the University of Delaware and a Master's in Bioengineering from Rice University . He is an accomplished inventor with over 50 US and international patent applications in various clinical specialties, including surgical oncology, laparoscopic surgery, and cardiovascular electrophysiology. Read more about Matthew here: https://lnkd.in/gj4RRPTa #Leadership #Innovation #MedTech #TaurusVascular #Healthcare #AorticAneurysms #BiomedicalEngineering #EVAR

We are proud to announce that Taurus Vascular has won the grand prize at the 10th Annual Texas A&M New Ventures Competition (TNVC). Competing against 20 of Texas' most promising startups, we are honored by this recognition. Our Co-founder and CEO, Matthew Kuhn , stated, “Winning first place at TNVC is a testament to our team's dedication and hard work. The financial support and increased visibility will be pivotal for our growth and partnerships. This award strengthens our mission to reduce endoleak risks in endovascular aortic aneurysm repair and improve patient care. We are also grateful to Biotex Inc for their sponsored prize and look forward to collaborating with them.” This achievement propels us further in our journey to revolutionize aortic aneurysm repair. Learn more about our mission here: https://lnkd.in/esdT-sFC #MedTech #Innovation #TaurusVascular #AorticAneurysms #Healthcare #Startup #TNVC #HealthcareInnovation

We’re excited to announce that we’ve successfully secured $1.3 million in seed funding! We are grateful for the confidence our investors have shown in our vision and their belief in the potential of our technology to transform the standard of care for aortic aneurysm treatment. As we continue to accelerate toward commercialization, we want to extend our gratitude to our mentors, investors, and all programs that continue to support us. Follow along on our journey for more updates! Matthew Kuhn | Founder & CEO William Cohn , MD | Founder & CMO #HealthTech #Innovation #MedicalDevices #Startup #TaurusVascular #MedTech #AorticAneurysms #AAA #TexasMedicalCenter #Healthcare #EVAR

At Taurus Vascular, we're on a mission to improve the lives of patients with aortic aneurysms. Every year, around 1 million people worldwide are diagnosed with an abdominal aortic aneurysm (AAA) - a condition where a part of the aorta, the largest artery in the body, becomes enlarged or balloons outward. This happens because the wall of the aorta can weaken due to a variety of factors, including age, smoking, and genetics. If the aneurysm gets too large, it can burst, causing serious internal bleeding, which is often life-threatening. Endovascular Aneurysm Repair (EVAR) is a pioneering procedure that has revolutionized the treatment of abdominal aortic aneurysms, however, it has also introduced some challenges. Unfortunately, up to 50% of patients treated via EVAR experience a complication called an “endoleak” - the leakage of blood into the aneurysm sac - resulting in ongoing aneurysm expansion and a continued risk of rupture. Despite the high frequency and seriousness of this complication, endoleaks have remained an urgent unmet clinical need for over two decades. Founded in 2023 from the Texas Medical Center Innovation Biodesign Program, Taurus Vascular is developing a novel catheter-based technology to address endoleaks. Our device creates a shunt to continuously drain endoleaks from the high-pressure aneurysm sac into the low-pressure venous system, promoting accelerated aneurysm shrinkage after endovascular aneurysm repair. Our journey has been filled with milestones like winning 1st Place at both the OPEN Houston Business Pitch Competition and the Texas A&M New Ventures Competition , acceptance into MedTech Innovator , being named one of the Top 10 Most Promising Life Science Companies at the BioHouston Texas Life Science Forum, and participating in several programs such as the University City Science Center Capital Readiness Program and accelerators including MassChallenge , OwlSpark , Octane OC , and LaunchPad SBDC . Follow our journey for more updates! Matthew Kuhn | Founder & CEO William Cohn , MD | Founder & CMO #HealthTech #Innovation #MedicalDevices #Startup #TaurusVascular #MedTech #AorticAneurysms #AAA #TexasMedicalCenter #Healthcare #EVAR

What a day! Congratulations to some of our TMC Biodesign companies who took home a few wins from Texas A&M New Ventures Competition . Taurus Vascular was selected as the First Place Finalist, securing $30,000, and received the Biotex Services Prize. Kudos to Ember Sleep for not only earning the Stibbs & Co. Legal Service Prize and the Winners’ Circle Legacy Prize but also coming in second place in the Elevator Pitch category, taking home $4,000. Congratulations to ParaDocs Health for winning the Capital Factory Investment & Services Prize and the Invincible Spaces Prize.

Texas Medical Center Innovation Factory

Squarespace Hosted

news impact assignment basic	general
public peers	general	Nov 17, 2024 9:33 PM	bbc1ae84
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 9:33 PM	dd60d8cb
crunchbase trigger	general	Nov 17, 2024 9:33 PM	612d892e
crunchbase profile	general	Nov 17, 2024 9:49 PM	370a5b94
li profile	general	Nov 17, 2024 9:33 PM	a3f9e5a1
translate crunchbase fundingrounds	general	Nov 17, 2024 10:14 PM	50ff6438
peers	general	Nov 17, 2024 9:33 PM	f372e01e
news basic	general	Nov 17, 2024 9:33 PM	2971e90e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

TAUR

COM:TAURUSVASCULAR

Taurus Vascular